ABSTRACT
Pollution is known to cause and exacerbate a number of chronic respiratory diseases. The World Health Organisation has placed air pollution as the world's largest environmental health risk factor. There has been recent publicity about the role for diet and anti-oxidants in mitigating the effects of pollution, and this review assesses the evidence for alterations in diet, including vitamin supplementation in abrogating the effects of pollution on asthma and other chronic respiratory diseases. We found evidence to suggest that carotenoids, vitamin D and vitamin E help protect against pollution damage which can trigger asthma, COPD and lung cancer initiation. Vitamin C, curcumin, choline and omega-3 fatty acids may also play a role. The Mediterranean diet appears to be of benefit in patients with airways disease and there appears to be a beneficial effect in smokers however there is no direct evidence regarding protecting against air pollution. More studies investigating the effects of nutrition on rapidly rising air pollution are urgently required. However it is very difficult to design such studies due to the confounding factors of diet, obesity, co-morbid illness, medication and environmental exposure.
Subject(s)
Air Pollutants/adverse effects , Diet, Mediterranean , Dietary Supplements , Environmental Exposure/adverse effects , Respiration Disorders/diet therapy , Respiration Disorders/etiology , Air Pollution/adverse effects , Antioxidants/administration & dosage , Ascorbic Acid/administration & dosage , Diet/methods , Fatty Acids, Omega-6/administration & dosage , Humans , Respiration Disorders/metabolismABSTRACT
We report the case of an asthmatic man with HIV infection who was initially diagnosed with HIV treatment-associated lipodystrophy. Further investigations showed he had Cushing's syndrome secondary to 1600 microg of budesonide dry powder inhaler. Cushing's syndrome has not been reported previously on this normal dose of inhaled budesonide.
Subject(s)
Adrenal Cortex Hormones/adverse effects , Budesonide/adverse effects , Cushing Syndrome/chemically induced , HIV Infections/drug therapy , Lipodystrophy/diagnosis , Administration, Inhalation , Adrenal Cortex Hormones/administration & dosage , Budesonide/administration & dosage , Cushing Syndrome/epidemiology , Diagnosis, Differential , HIV Infections/complications , Humans , Lipodystrophy/etiology , Male , Middle AgedABSTRACT
The case is described of a potentially life threatening complication relating to the use of a totally implantable venous access device (Port-a-Cath) in a 28 year old patient with cystic fibrosis. The device was inserted in 1990 and used repeatedly for antibiotic therapy without any complications. In 1995, during assessment for double lung transplantation, a 3 cm thrombus was found at the tip of the catheter in the right atrium. Embolisation of the thrombus to the pulmonary arteries occurred after the infusion of recombinant tissue plasminogen activator (rt-PA). Thrombus formation may be associated with totally implantable venous access devices and thromboembolism may occur following the use of thrombolytic agents in the treatment of such thrombosis.
Subject(s)
Cystic Fibrosis/therapy , Infusion Pumps, Implantable/adverse effects , Pulmonary Embolism/etiology , Tissue Plasminogen Activator/adverse effects , Adult , Female , HumansABSTRACT
Alpha 1-antitrypsin deficiency is associated with pulmonary emphysema and liver cirrhosis. The pathogenesis and treatment is reviewed with particular emphasis on gene therapy for emphysema. The technology of gene transfer using viruses and liposomes is developing fast and animal experiments have confirmed the feasibility of gene therapy for alpha 1-antitrypsin deficiency (AATD). So far only subtherapeutic levels of protein have been produced but human trials are starting and progress can be expected.
